INFO & CONTACTS:  +39 02 2390 1

Circulating EBV-DNA changes in tailoring treatment of locally advanced nasopharyngeal carcinoma: the phase 2 trial INTERLAYER

Principal Investigator: Dott. Alfieri Salvatore

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: Gemcitabina 1000 mg/mq

Cisplatino 100 mg/mq

Radioterapia

Capecitabina 650 mg/mq

Pathologies: Other

NPC is a rare disease in non-endemic areas with an estimated incidence of 0.4 per 100.000 in Europe. NPC is also known to be highly sensitive to radiotherapy and chemotherapy and its prognosis has remarkably improved in the past decades with a 5-years OS rate varying from 98% to 71% according to the staging group. However, there are two main unmet needs in this setting: reduce the toxicities burden in the subset of patients with good prognosis and increase survival in the one with poor prognosis. 

Since this is a cancer related to the virus (EBV), the evaluation of the longitudinal trend of the virus itself can represent a method for analyzing the disease's response to treatments. The protocol will accrue up to 70 total patients, divided into 3 different prognostic cohorts according to longitudinal EBV-DNA assays performed after the end of each IC cycle. 

Main inclusion criteria: 

  • Histologically proven diagnosis of EBV-related NPC 
  • Stage III-IV according to American Joint Committee on Cancer (AJCC) 8th edition 
  • Detectable pre-treatment plasma EBV-DNA 

Main exclusion criteria: 

  • Recurrent/metastatic NPC 
  • Prior local or systemic treatment for NPC 
  • Diagnosis of other malignancies (except for tumours with low risk of recurrence) 

The feasibility of enrollment in the study depends on patient characteristics (demographics, oncological history, and comorbidities), laboratory tests, and radiological parameters, which will be assessed through specific screening examinations before starting treatment. These assessments will be performed at this institution according to well-defined timelines. 

Eligible patients will undergo 3 cycles of induction chemotherapy (IC) with cisplatin-gemcitabine (d1,8q21) and EBV-DNA assay will be performed after each cycle of IC. Patients with undetectable EBV-DNA after 1 IC cycle and radiological PR or CR will receive deescalated chemoradiation therapy (CRT) (DE-ESCALATION COHORT); patients with undetectable EBV-DNA after more than 1 IC cycle will receive standard concurrent CRT (STANDARD COHORT); patient with persistent detectable EBV-DNA or undetectable EBV-DNA at any time of IC and subsequent bounce during treatment will receive standard CRT followed by adjuvant metronomic capecitabine for up to 1 year (ESCALATION COHORT). 

The treatment schedule will be as follows: 

  • Cohort A: undetectable EBV-DNA after 1 IC cycle and radiological PR or CR > DE-ESCALATION > Cisplatin 100 mg/mq every 3 weeks for 2 cycles and RT; 

 

  • Cohort B: undetectable EBV-DNA after more than 1 IC cycle > STANDARD > Cisplatin 100 mg/mq every 3 weeks for 3 cycles and RT; 

 

 

  • Cohort C: persistent detectable EBV-DNA or undetectable EBV-DNA at any time of IC and subsequent bounce > ESCALATION > Cisplatin 100 mg/mq every 3 weeks for 3 cycles, RT e capecitabine per 1 year.  

 

Treatment will continue until maximum response is achieved and in accordance with the study protocol. Treatment will be discontinued in case of disease progression, unacceptable toxicity, or, as always in clinical trials, if decided by either the investigator or the patient (who will nonetheless continue to have access to medical care and will not forfeit any legal rights or benefits to which they are entitled). 

Patients will also be monitored for adverse events caused by chemotherapy. In such cases, the investigators will propose symptomatic therapies and implement targeted strategies to reduce the intensity of these side effects (e.g., therapeutic pauses, dose reductions, corticosteroid-based treatments, etc.). To ensure patient safety from the toxicities of chemotherapy, study participants will be closely monitored. 

The study team remains available for more detailed information (email: amo@istitutotumori.mi.it). 

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe